Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE-CIN
ChiCTR2600133349Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tafolecimab in contrast-induced nephropathy (CIN) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Incidence of contrast-induced acute kidney injury. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR2600133349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133349.